Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...
Increased Investment In Biotechnology: A Key Driver Transforming The Cas Nuclease Market 2024
The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...
Vertex’s Growth Potential and Raised Price Target Amidst ERP Supercycle and E-Invoicing Expansion
Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...
CC Chemokine Receptor Type 5 Market Research Report 2024
The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...
Stop abuse of patent monopolies in rare diseases, say patient representatives and treatment activists
with no options for the drug becoming available to patients in India in sight. The drug for CF (CFTR modulators), while under monopoly, continues to be unavailable in the country due to a lack of ...
health.economictimes.indiatimes7d
Patents and high price barriers: Patients with rare diseases face woes to access medicines from MNCs
Patients with rare diseases in India, like Saifullah Khalidi with spinal muscular atrophy (SMA), struggle to afford ...
Rare diseases patient representatives seek govt intervention to access treatment
Patient advocates push for generic drug production to treat rare diseases, facing patent barriers and high costs.
Reuters on MSN8d
Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength
Vertex Pharmaceuticals raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its ...
Share Market Highlights: Sensex, Nifty mark worst drop in over a month amid US election jitters
Shares of Sun Pharmaceutical fell 2.64 per cent after the pharma major ... Fitch Ratings - Singapore - 04 Nov 2024: Fitch ...
How Asian pharma suppliers cash in on Ozempic copies
Just over a year ago, New Zealand customs officials started to intercept batches of injectable medications labelled Fitaro ...
Bosch cuts revenue forecast for coming year, layoffs not ruled out
The chairman of German auto parts supplier Robert Bosch (ROBG.UL) warned on Thursday of declining revenue in the coming year, and said he cannot rule out further job cuts in Germany in addition to the ...